Indoco Remedies Limited (BOM:532612)
India
· Delayed Price · Currency is INR | Market Cap | 21.45B |
| Revenue (ttm) | 17.24B |
| Net Income (ttm) | -106.60M |
| Shares Out | n/a |
| EPS (ttm) | -1.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 1.50 (0.61%) |
| Ex-Dividend Date | Sep 19, 2024 |
| Volume | 1,357 |
| Average Volume | 16,416 |
| Open | 243.15 |
| Previous Close | 242.15 |
| Day's Range | 240.50 - 248.75 |
| 52-Week Range | 190.00 - 385.50 |
| Beta | n/a |
| RSI | 45.78 |
| Earnings Date | May 16, 2025 |
About Indoco Remedies
Indoco Remedies Limited manufactures, markets, and sells formulations and active pharmaceutical ingredients in India and internationally. It offers stomatological, gastrointestinal, respiratory, anti-infectives, vitamins/minerals/nutrients, ophthal/ontological, dermatology, urological, anti-diabetic, gynaecological, lifestyle management, pain/analgesic, and cardiac products. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; a... [Read more]
Financial Performance
In 2023, Indoco Remedies's revenue was 18.17 billion, an increase of 8.91% compared to the previous year's 16.69 billion. Earnings were 984.60 million, a decrease of -30.78%.
Financial StatementsNews
Indoco Remedies Q3 FY25 Results: Revenue declines 6.2% YoY to Rs 410.55 crore; Net loss widens to Rs 28.40 crore
Indoco Remedies Limited released its financial results for the quarter ending December 31, 2024 (Q3 FY25), reporting a decline in revenue and a net loss due to increased expenses and operational chall...
Indoco Remedies shares plunge over 7% as Goa facility receives USFDA warning letter
Indoco Remedies’ shares fell sharply by 7.52% today following a significant setback, as the company’s Goa facility, contributing 65-70% of its revenue, received a warning letter from the USFDA. The wa...
Indoco Remedies receives USFDA warning letter for Goa facility
Indoco Remedies has received a warning letter from the USFDA for its Goa facility, following an inspection conducted from July 16-26, 2024. This follows the earlier notification on October 11, 2024, w...
Indoco Remedies stock surges 8% on partnership with Clarity Pharma in the UK
Indoco Remedies witnessed a significant 8% jump in its stock price following the announcement of a strategic distribution partnership with Clarity Pharma, UK. This collaboration is set to launch appro...
Indoco Remedies partners with Clarity Pharma to strengthen UK presence
The partnership combines Indoco’s robust portfolio of high-quality, affordable pharmaceutical products with Clarity Pharma’s extensive distribution network and market expertise.